iShares MSCI South Korea ETF vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? iShares MSCI South Korea ETF trades at $177.06 (market cap $26.25B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.7 (market cap $2.27B). The key difference: iShares MSCI South Korea ETF is far larger — about 11.6× SELLAS Life Sciences Group Inc. Common Stock's market cap, and iShares MSCI South Korea ETF is more actively traded (19,056,075 versus 4,179,659). Which is the better fit depends on your goals.
| EWY | SLS | |
|---|---|---|
Market Cap | $26.25B | $2.27B |
Volume | 19,056,075 | 4,179,659 |
Sector | Broad Market / Factor | Health |
52-Week High | $219.20 | $15.46 |
52-Week Low | $80.72 | $1.39 |
Typical Hold Time | 46 Days | — |
Enterprise Value | — | $2.14B |
Signals from Pluang's Aura AI — not financial advice
EWY (iShares MSCI South Korea ETF) is trading at $176.77, down 3.78% amid broader Asian market pressures. The ETF shows a bearish technical signal with moving averages indicating selling pressure, though oversold RSI levels suggest potential near-term support. Recent volatility reflects sensitivity to semiconductor cycles, with heavy concentration in Samsung and SK hynix driving performance. South Korea's KOSPI has struggled to maintain gains above 7,000 despite AI-driven optimism, facing headwinds from rising oil prices and global bond yields.
The outlook remains tied to semiconductor demand and AI infrastructure spending, with corporate earnings showing resilience. Key risks include concentration in two holdings, memory cycle dependency, and macroeconomic pressures. Governance reforms and visible deleveraging provide fundamental support, but the ETF's high sensitivity to tech sector volatility warrants caution for risk-averse investors.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →